In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of ...

In the SURPASS-CVOT trial, tirzepatide was similar to dulaglutide for prevention of cardiovascular death, heart attack and stroke at 4 years, researchers reported at the European Association for the ...

A new large-scale study came to the conclusion that weight-loss surgery gives people with type 2 diabetes and obesity a ...

Continuing the upmanship battle in expanding the use of GLP-1 drugs beyond diabetes and obesity, Novo Nordisk has released ...

SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

A pharmacist with 30 years experience says she would never take weight loss drugs as 'alarming' side effects are coming to ...

A pharmacist with 30 years experience says she would never take weight loss drugs as 'alarming' side effects are coming to ...

Lilly’s cardiovascular outcomes trial is the first to use an active comparator, finding noninferiority but not superiority of ...

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

The REACH study included data from 58,336 Medicare patients aged 66 years and older with T2D and ASCVD who had initiated either semaglutide or dulaglutide.

Novo Nordisk's Ozempic reduces the risk of heart attack, stroke and death by 23% in people with type 2 diabetes and cardiovascular disease compared to rival drug dulaglutide, the company said Thursday ...

Weight-loss medications reduced body weight in children and teens, but the sample size was too small to make conclusions ...